読み込み中
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
前日終値
$1.27
−$0.03 · -2.31%
日中の時刻はETです。市場データは遅延する場合があります。
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
日中レンジ
現在 $1.27
52週レンジ
現在 $1.27
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
27
割高
センチメント
45
まちまち
リスク
69
高リスク
モメンタム
36
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
日中レンジ
現在 $1.27
52週レンジ
現在 $1.27
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 4.6万 USD | — | — | — | 51.9万 USD |
| 粗利益 | −4.6万 USD | — | — | — | −51.9万 USD |
| 研究開発 | 1523.4万 USD | 1447.8万 USD | 1585.9万 USD | 835万 USD | 1890.3万 USD |
| 販売・一般管理 | 788.7万 USD | 972.6万 USD | 2221.6万 USD | 584.3万 USD | 1704.4万 USD |
| 営業費用 | 2312.1万 USD | 2420.4万 USD | 3807.5万 USD | 1419.3万 USD | 3542.8万 USD |
| 受取利息 | 71.3万 USD | — | — | — | 12.6万 USD |
| 支払利息 | 142.2万 USD | — | 11万 USD | 13.2万 USD | 12.6万 USD |
| 減価償却費と償却費 | 4.6万 USD | 5.8万 USD | 5.8万 USD | 5.2万 USD | 51.9万 USD |
| 営業利益 | −2312.1万 USD | −2420.4万 USD | −3807.5万 USD | −1419.3万 USD | −3594.7万 USD |
| 純利益 | −2956.2万 USD | −1370万 USD | −3435.7万 USD | −782.4万 USD | −3582.1万 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$266
上昇余地（20844.88%）この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
